CW
Therapeutic Areas
Fulcrum Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Losmapimod (FHD-286) | Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 3 |
| FTX-6058 | Sickle Cell Disease | Phase 1b |
| FHD-909 | Chronic Obstructive Pulmonary Disease (COPD) | Preclinical |
Leadership Team at Fulcrum Therapeutics
BE
Bryan E. Stuart
President and Chief Executive Officer
RJ
Robert J. Gould, Ph.D.
Chairman of the Board
ER
Esther Rajavelu
Chief Financial Officer
CM
Chris Moxham, Ph.D.
Chief Scientific Officer
JD
Judith Dunn, Ph.D.
President of Research and Development
DL
Daniel L. Karp, M.D.
Chief Medical Officer
OH
Owen Hughes
Chief Business Officer
AB
Alexis Borisy
Director
KH
Kate Haviland
Director
CS
Catherine Stehman-Breen, M.D.
Director